FDA, FTC Join Forces To Eliminate Barriers To Biosimilar Competition

Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.

Conceptual business illustration with the words anti-competitive practices — FDA and FTC to target anticompetitive behavior that impedes access to biosimilars

Biologic manufacturers could face a wave of enforcement actions against behavior that impedes the marketing of biosimilars as the US Food and Drug Administration and Federal Trade Commission are teaming up to promote competition in biologics markets.

The two agencies issued a 3 February joint statement in which they committed to strengthening efforts to curtail and...